Chemomab Therapeutics Ltd. announced that Adi Mor, PhD, co-Founder and former Chief Executive Officer (CEO) of Chemomab, and current Director and Chief Scientific Officer, has been reappointed to the role of CEO, replacing Dale Pfost, PhD. All the appointments were effective June 1, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.86 USD | +2.26% | +5.65% | +68.63% |
05-06 | Oppenheimer Upgrades Chemomab Therapeutics to Outperform | MT |
04-10 | Transcript : Chemomab Therapeutics Ltd. - Special Call |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+68.63% | 11.95M | |
+9.58% | 115B | |
+12.41% | 106B | |
-2.59% | 21.96B | |
-12.38% | 21.87B | |
-5.29% | 19.21B | |
-3.35% | 18.08B | |
-38.57% | 17.71B | |
+7.51% | 14.32B | |
+35.67% | 12.42B |
- Stock Market
- Equities
- CMMB Stock
- News Chemomab Therapeutics Ltd.
- Chemomab Therapeutics Ltd. Names Adi Mor, Phd as CEO